3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
151
Breast Neoplasms
116
Carcinoma, Non-Small-Cell Lung
65
Triple Negative Breast Neoplasms
45
Neoplasms
44
Neoplasm Metastasis
44
Lung Neoplasms
26
Ovarian Neoplasms
25
Squamous Cell Carcinoma of Head and Neck
24
Stomach Neoplasms
22
Melanoma
16
Esophageal Neoplasms
16
Adenocarcinoma
15
Head and Neck Neoplasms
13
Recurrence
12
Esophageal Squamous Cell Carcinoma
12
Cholangiocarcinoma
12
Sarcoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Small Cell Lung Carcinoma
10
Fallopian Tube Neoplasms
10
Uterine Cervical Neoplasms
9
Urinary Bladder Neoplasms
8
Pancreatic Adenocarcinoma
8
Colorectal Neoplasms
8
Prostatic Neoplasms
7
Inflammatory Breast Neoplasms
7
Carcinoma, Pancreatic Ductal
7
Breast Neoplasms, Male
7
Biliary Tract Neoplasms
7
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non Small Cell Lung Cancer NSCLC
×
Albumin-Bound Paclitaxel
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA